Roche (OTCQX:RHHBY) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple sclerosis therapy announced two Phase 3 trial successes for fenebrutinib, its new experimental drug ...

Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.

– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in ...

Add Yahoo as a preferred source to see more of our stories on Google. The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File ...

Roche Holding said a drug candidate for multiple sclerosis met the primary goal in a late-stage clinical trial in the most common form of the disease. The Swiss pharmaceutical company said Monday that ...

Roche Holding said a drug candidate for multiple sclerosis met the primary goal in a late-stage clinical trial for the most common form of the disease. The Swiss pharmaceutical company said Monday ...

Swiss pharmaceuticals powerhouse Roche announced on Saturday that the company’s experimental multiple sclerosis drug met its primary goal in a late-stage trial in patients with a rare form of the ...

Roche Holding said a drug candidate for multiple sclerosis met the primary goal in a late-stage clinical trial in the most common form of the disease. The Swiss pharmaceutical company said Monday that ...